(Q26828463)

English

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

scientific article

In more languages

Statements

scholarly article

1 reference

5 references

25 April 2019

30 June 2019

12 September 2019

21 January 2021

29 April 2021

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis (English)

1 reference

0 references

multiple sclerosis

3 references

25 April 2019

30 June 2019

12 September 2019

1 reference

12 September 2019

person with disabilities

1 reference

21 January 2021

1 reference

29 April 2021

systematic review

1 reference

based on heuristic

inferred from title

regression analysis

1 reference

based on heuristic

inferred from title

author name string

Kyle Fahrbach

1

1 reference

Rachel Huelin

2

1 reference

Amber L Martin

3

1 reference

Edward Kim

4

1 reference

Homa B Dastani

5

1 reference

Stephen Rao

6

1 reference

Manoj Malhotra

7

1 reference

language of work or name

1 reference

publication date

19 November 2013

6 references

25 April 2019

30 June 2019

12 September 2019

21 January 2021

29 April 2021

6 references

25 April 2019

30 June 2019

12 September 2019

21 January 2021

29 April 2021

13

1 reference

180

1 reference

copyright license

Creative Commons Attribution 2.0 Generic

5 references

Europe PubMed Central

25 April 2019

Europe PubMed Central

30 June 2019

Europe PubMed Central

12 September 2019

Europe PubMed Central

21 January 2021

Europe PubMed Central

29 April 2021

copyright status

0 references

on focus list of Wikimedia project

0 references

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

7 April 2017

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 September 2017

Demyelination versus remyelination in progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-13-180

21 January 2018

A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4225567

28 November 2018

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of relapses to disability in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24245966

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2377-13-180

1 reference

Dimensions Publication ID

0 references

release_r22ganlj75f67nxkzsjsrbleja

0 references

PMC publication ID

1 reference

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26828463&oldid=2177275140"